Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Solange Peters

Showing results (291-300 of 362) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2024
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid TumorsSolange Peters, Eric Angevin, Teresa Alonso-Gordoa, et al.
Revue Medicale Suisse|January 17, 2024
[Oncology: what's new in 2023]Jeremy Jankovic, Karim Abdelhamid, Dominik Berthold, et al.
Lancet (London, England)|July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled studySiow Ming Lee, Christian Schulz, Kumar Prabhash, et al.
Future Oncology (London, England)|May 20, 2025
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)Siow Ming Lee, Christian Schulz, Anne-Marie Baird, et al.
Cancer Immunology Research|November 25, 2024
Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint InhibitionYameng Hao, Aspasia Gkasti, Amy J Managh, et al.
Nature Medicine|August 22, 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialSolange Peters, Rafal Dziadziuszko, Alessandro Morabito, et al.
The Oncologist|September 5, 2024
Proceedings of the 1st biannual bridging the gaps in lung cancer conferenceNarjust Florez, Sandip P Patel, Heather Wakelee, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2025
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trialMatthias Guckenberger, Isabelle Opitz, Tereza Dellaporta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
Pageof 37

Showing results (291-300 of 362) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2024
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid TumorsSolange Peters, Eric Angevin, Teresa Alonso-Gordoa, et al.
Revue Medicale Suisse|January 17, 2024
[Oncology: what's new in 2023]Jeremy Jankovic, Karim Abdelhamid, Dominik Berthold, et al.
Lancet (London, England)|July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled studySiow Ming Lee, Christian Schulz, Kumar Prabhash, et al.
Future Oncology (London, England)|May 20, 2025
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)Siow Ming Lee, Christian Schulz, Anne-Marie Baird, et al.
Cancer Immunology Research|November 25, 2024
Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint InhibitionYameng Hao, Aspasia Gkasti, Amy J Managh, et al.
Nature Medicine|August 22, 2022
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trialSolange Peters, Rafal Dziadziuszko, Alessandro Morabito, et al.
The Oncologist|September 5, 2024
Proceedings of the 1st biannual bridging the gaps in lung cancer conferenceNarjust Florez, Sandip P Patel, Heather Wakelee, et al.
Lung Cancer (Amsterdam, Netherlands)|May 1, 2025
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trialMatthias Guckenberger, Isabelle Opitz, Tereza Dellaporta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451Taofeek K Owonikoko, Keunchil Park, Ramaswamy Govindan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
Pageof 37